Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CareDxSTU:1K9 73 Pretax Margin % is 2.36% as of Mar. 2026. GuruFocus rates STU:1K9 with a GF Score™ of 73/100 and a GF Value™ of €18.75 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, CareDx ranks better than 51.49% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. CareDx's Pre-Tax Income for the
three
months ended in Mar. 2026 was €2.4 Mil. CareDx's Revenue for the
three
months ended in Mar. 2026 was €101.8 Mil. Therefore, CareDx's pretax margin for the quarter that ended in Mar. 2026 was 2.36%.
The historical rank and industry rank for CareDx's Pretax Margin % or its related term are showing as below:
STU:1K9'
s Pretax Margin % Range Over the Past 10 Years
Min: -118.51 Med: -21.27 Max: 15.84
Current: -1.94
STU:1K9's Pretax Margin % is ranked better than 51.49% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.565
vs STU:1K9: -1.94
CareDx (STU:1K9) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
CareDx Pretax Margin % Related Terms
CareDx Pretax Margin % Historical Data
* Premium members only.
The historical data trend for CareDx's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1K9 vs PSNL, OPK, NEO: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, CareDx's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CareDx Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, CareDx's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where CareDx's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CareDx (STU:1K9) has a Pretax Margin % of 2.36% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on CareDx and its competitors. According to the industry distribution chart, CareDx ranks #98 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 48.5%.
Is CareDx's Pretax Margin % too high?
CareDx's current Pretax Margin % is 2.36%. Based on the distribution chart, CareDx ranks #98 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, CareDx has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CareDx's Pretax Margin % compare to PSNL and OPK?
According to the Medical Diagnostics & Research industry distribution chart, CareDx ranks #98 out of 202 companies for Pretax Margin %. This puts CareDx in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on CareDx and its competitors. CareDx's current Pretax Margin % is 2.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CareDx stock overvalued right now?
Based on GuruFocus' analysis, CareDx (STU:1K9) is currently considered Significantly Overvalued. The stock's GF Value™ is €18.75, compared to a current price of €33.00 — trading 76% above its estimated fair value. The current Pretax Margin % is 2.36%. CareDx's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For CareDx (STU:1K9), the current Pretax Margin % is 2.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CareDx (STU:1K9) Overvalued in 2026?
Based on GuruFocus' analysis, CareDx stock appears to be overvalued.
The current stock price of €33.00 is trading 76% above its estimated GF Value™ of €18.75.
GuruFocus considers CareDx to be Significantly Overvalued.
Key valuation signals for STU:1K9:
Pretax Margin %: 2.36%
GF Value™: €18.75 vs. price of €33.00 (76% above fair value)
No single metric tells the full story. See the STU:1K9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
73GF Score
Get the complete analysis for STU:1K9
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1K9 has been successfully added to your 
